Published in:
01-09-2009 | Urology - Original Paper
Effect of intralesional verapamil for treatment of Peyronie’s disease: a randomized single-blind, placebo-controlled study
Published in: International Urology and Nephrology | Issue 3/2009
Login to get accessAbstract
Purpose
We aimed to assess the effect of intralesional verapamil on the treatment of Peyronie’s disease.
Materials and methods
This randomized study involved 80 patients. First, they were divided into two groups. The first group (case: 40 patients) received intralesional verapamil and the second group (control: 40 patients) local saline injection. They were followed about 24 weeks and evaluated for the size of plaques, plaque softening, reduction of pain and amelioration of penile deformity and erectile dysfunction (estimated by the International Index of Erectile Function) before and after treatment.
Results
Reduction of plaque size was seen in 17.5% of the case group and 12.8% of the control group (P: 0.755). Pain was reduced in 30% of the case group and 28.2% of the control group (P: 0.99). Curvature was decreased in 17.5% of the case group and 23.1% the control group (P: 0.586). Plaque softening was seen in 30% of the case group compared with 25.6% improvement in the control group (P: 0.803).
Also we found 5% and 2.6% improvement in sexual dysfunction in the case and control groups, respectively. (P: 0.985).
Conclusion
Although in some studies verapamil has been found to be effective in the treatment of Peyronie’s disease, we did not find any improvement in comparison with the control group.
Furthermore, larger scale studies are warranted to assess the effect of this drug on the treatment of Peyronie’s disease.